The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis,
prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The
present invention furthermore relates to monitoring the effect of a treatment against renal cell
carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the
treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention
furthermore relates to panels of cellular biomarkers for use in the above methods, in particular
multicolor panels for measuring said biomarkers